About this Research Topic
Urothelial carcinoma (UC), which includes both bladder cancer and upper tract urothelial carcinoma (UTUC), remains one of the most aggressive and challenging cancers to treat. Despite advancements in medical science, these cancers continue to be characterized by high recurrence rates and poor prognosis. Significant efforts have been made to improve patient outcomes, yet there is still much work to be done to develop more effective therapies and enhance survival rates. The complexity of UC demands ongoing research and innovation to better understand the disease and identify novel treatment strategies.
In recent years, there have been notable advancements in both surgical and systemic treatments for UC. Surgical techniques have evolved, with minimally invasive approaches such as robotic-assisted surgeries improving patient recovery times and reducing complications. On the systemic treatment front, the development of more effective chemotherapy regimens has been crucial. Moreover, the rise of immunotherapy has revolutionized the treatment landscape for UC. Immune checkpoint inhibitors have shown promising results, providing new hope for patients with advanced or metastatic disease. These therapies work by enhancing the body’s immune response against cancer cells, potentially leading to longer-lasting remissions and improved survival rates.
The goal of this Research Topic is to gather comprehensive evidence on the advancements in the treatment of urothelial carcinoma of the bladder and upper tract. We aim to explore both surgical innovations and medical therapies, providing a holistic view of the current progress and future directions in UC treatment. Contributions that delve into the impact of new surgical techniques, the efficacy of systemic treatments, and the role of immunotherapy are particularly welcome. We invite Original Research, Reviews, Systematic Reviews, and Mini-Reviews to enrich our understanding and guide future clinical practices.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In recent years, there have been notable advancements in both surgical and systemic treatments for UC. Surgical techniques have evolved, with minimally invasive approaches such as robotic-assisted surgeries improving patient recovery times and reducing complications. On the systemic treatment front, the development of more effective chemotherapy regimens has been crucial. Moreover, the rise of immunotherapy has revolutionized the treatment landscape for UC. Immune checkpoint inhibitors have shown promising results, providing new hope for patients with advanced or metastatic disease. These therapies work by enhancing the body’s immune response against cancer cells, potentially leading to longer-lasting remissions and improved survival rates.
The goal of this Research Topic is to gather comprehensive evidence on the advancements in the treatment of urothelial carcinoma of the bladder and upper tract. We aim to explore both surgical innovations and medical therapies, providing a holistic view of the current progress and future directions in UC treatment. Contributions that delve into the impact of new surgical techniques, the efficacy of systemic treatments, and the role of immunotherapy are particularly welcome. We invite Original Research, Reviews, Systematic Reviews, and Mini-Reviews to enrich our understanding and guide future clinical practices.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: urothelial cancer, oncology, genitourinary, bladder, cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
